AR058095A1 - Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas. procesos de obtencion y composiciones farmaceuticas. - Google Patents

Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas. procesos de obtencion y composiciones farmaceuticas.

Info

Publication number
AR058095A1
AR058095A1 ARP060104518A ARP060104518A AR058095A1 AR 058095 A1 AR058095 A1 AR 058095A1 AR P060104518 A ARP060104518 A AR P060104518A AR P060104518 A ARP060104518 A AR P060104518A AR 058095 A1 AR058095 A1 AR 058095A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
cycloalkyl
aryl
amino
Prior art date
Application number
ARP060104518A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR058095A1 publication Critical patent/AR058095A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1) en la que los significados son X de manera idéntica o diferente, =C(-R)- o =N-, en que al menos uno y a lo sumo dos X es/son =N-; W -(C=O)-, -(S=O)-, -(SO2)-; R de manera idéntica o diferente, hidrogeno, halogeno, alquilo (C1-6), haloalquilo (C1-3), alquiloxi (C1-3)-alquileno C1-3), hidroxi, fenoxi, amino, alquil (C1-6)-amino, di-alquil (C2-12)-amino, ciano, nitro, COOR3, mono-alquil (C1-6)-aminocarbonilo, di-alquil (C2-8)-aminocarbonilo, alquil (C1-6)-mercapto, alquil (C1-6)-sulfinilo, alquil (C1-6)-sulfonilo, aminosulfonilo, pentafluorosulfanilo, arilo, heteroarilo, cicloalquilo (C3-12), alquil (C1-6)-carbonilo, O-CO-NR3R3a, O-CO-alquilen (C1-6)-CO-O-alquilo (C1-6), O-CO-alquilen (C1-6)-CO-OH, O-CO-alquilen (C1-6)-CO-NR3R3a o alquiloxi (C1-6) no sustituido o mono- o poli-F-sustituido; R1 alquilo (C5-16), cicloalquilo (C5-12), Y-arilo, Y-heteroarilo, Y-cicloalquilo (C5-12), biciclo, en que arilo, heteroarilo, cicloalquilo o biciclo puede estar sustituido, una o más veces, con halogeno, alquilo (C1-6), alquiloxi (C1-6), hidroxi, alquil (C1-6)-mercapto, amino, alquil (C1-6)-amino, di-alquil (C2-12)-amino, mono-alquil (C1-6)-aminocatbonilo, di-alquil (C2-8)- aminocarbonilo, alquiloxi (C1-6)-carbonilo, alquil (C1-6)-carbonilo, ciano, nitro, trifluorometilo, trifluorometoxi, alquil (C1-6)-sulfonilo, aminosulfonilo; Y alquileno (C1-3), que puede estar sustituido, una o más veces, con halogeno, alquilo (C1- 2) o hidroxi; R2 hidrogeno, alquilo (C4-12); o R1 y R2, junto con el átomo de nitrogeno que los porta, pueden formar un sistema de anillo de 4 a 7 miembros, monocíclico, saturado o parcialmente insaturado o un sistema de anillo de 8 a 14 miembros, bicíclico, saturado o parcialmente insaturado, cuyos miembros individuales de los sistemas de anillo pueden estar reemplazados por uno a tres átomos o grupos atomicos de la serie -CHR4-, -CR4R5-, =(C-R4)-, -NR5-, -C(=O)-, -O-, -S-, -SO-, -SO2-, con la condicion de que dos unidades de la serie -O-, -S-, -SO-, -SO2- no puedan estar adyacentes; R3, R3a, de manera idéntica o diferente, hidrogeno, alquilo (C1-6), bencilo; R4, R5, de manera idéntica o diferente, alquilo (C1-12), alquiloxi (C1-6), halogeno, haloalquilo (C1-3), haloalquiloxi (C1-3), COOR3, nitro, ciano, arilo, heterociclo, cicloalquilo (C3-12), alquilen (C1-3)-arilo, alquilen (C1-3)-heterociclo, alquilen (C1-3)-cicloalquilo, en que arilo, heterociclo o cicloalquilo puede estar sustituido, una o más veces, con halogeno, alquilo (C1-6), alquiloxi (C1-6), O-alquilen (C1-3)-arilo, trifluorometilo, trifluorometoxi, hidroxi, mono-alquil (C1-6)-aminocarbonilo, di-alquil (C2-8)-aminocarbonilo, CO-alquilo (C1-6), CO-O-alquilo (C1- 6), NR3R3a; las formas tautomeras de los compuestos y sus sales fisiologicamente toleradas; con la condicion de que debe excluirse el compuesto de la formula 1 con los significados X en las posiciones 4, 5 y 6 = =C(-R)-, en la posicion 7 = =N-, W = - (C=O)-, R = hidrogeno, R1 y R2 forman una morfolina; y con la condicion de que deben excluirse loc compuestos de la formula 1 con los significados X en las posiciones 4 y 6 = =C(-R)-, en las posiciones 5 y 7 = =N-, W = -(C=O)-, R = arilo, heteroarilo, fenoxi.
ARP060104518A 2005-10-19 2006-10-17 Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas. procesos de obtencion y composiciones farmaceuticas. AR058095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005049954A DE102005049954A1 (de) 2005-10-19 2005-10-19 Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen

Publications (1)

Publication Number Publication Date
AR058095A1 true AR058095A1 (es) 2008-01-23

Family

ID=37487398

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104518A AR058095A1 (es) 2005-10-19 2006-10-17 Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas. procesos de obtencion y composiciones farmaceuticas.

Country Status (26)

Country Link
US (2) US7718669B2 (es)
EP (1) EP1940838B1 (es)
JP (1) JP2009512649A (es)
KR (1) KR20080057299A (es)
CN (1) CN101291932A (es)
AR (1) AR058095A1 (es)
AU (1) AU2006303551A1 (es)
BR (1) BRPI0617712A2 (es)
CA (1) CA2625442A1 (es)
CR (1) CR9851A (es)
DE (1) DE102005049954A1 (es)
DO (1) DOP2006000227A (es)
EC (1) ECSP088376A (es)
HN (1) HN2006035237A (es)
IL (1) IL190715A0 (es)
MA (1) MA29857B1 (es)
MY (1) MY140514A (es)
NO (1) NO20082159L (es)
NZ (1) NZ567574A (es)
PE (1) PE20070820A1 (es)
RU (1) RU2008119435A (es)
TN (1) TNSN08178A1 (es)
TW (1) TW200800987A (es)
UY (1) UY29878A1 (es)
WO (1) WO2007045392A1 (es)
ZA (1) ZA200802369B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005049954A1 (de) * 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
SI1976828T1 (sl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Diaminski derivati kot inhibitorji levkotrien A4 hidrolaze
FR2915197B1 (fr) 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
FR2915198B1 (fr) * 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
FR2915199B1 (fr) * 2007-04-18 2010-01-22 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
EP2351744B1 (en) 2008-10-17 2015-01-07 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase
JP5657566B2 (ja) * 2008-12-24 2015-01-21 バイアル ポルテラ アンド シーエイ エス エイＢＩＡＬ−Ｐｏｒｔｅｌａ ＆ Ｃａ， Ｓ．Ａ． 医薬品
CN102753545A (zh) 2009-12-15 2012-10-24 盐野义制药株式会社 具有血管内皮脂酶抑制活性的噁二唑衍生物
KR20130087002A (ko) 2010-06-04 2013-08-05 알바니 몰레큘라 리써치, 인크. 글리신 수송체-1 저해제, 그의 제조 방법 및 그의 용도
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
BR112015022227A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
RU2678196C2 (ru) 2013-03-14 2019-01-24 Селтакссис, Инк. Производные 2-фениламино-3-цианопиразоло[1,5-а]пиримидина, полезные в качестве ингибитора лейкотриен-a4-гидролазы
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
US9580422B2 (en) * 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP3137168B1 (en) 2014-04-30 2022-01-05 The Trustees of Columbia University in the City of New York Substituted 4-phenylpiperidines, their preparation and use
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法
CN117126134A (zh) * 2022-05-20 2023-11-28 中国科学院上海药物研究所 新型四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
DE10247680B4 (de) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
DE102004005172A1 (de) * 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
DE102005049954A1 (de) * 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen

Also Published As

Publication number Publication date
NO20082159L (no) 2008-05-08
CR9851A (es) 2008-07-29
ECSP088376A (es) 2008-05-30
DE102005049954A1 (de) 2007-05-31
MA29857B1 (fr) 2008-10-03
TNSN08178A1 (en) 2009-10-30
MY140514A (en) 2009-12-31
JP2009512649A (ja) 2009-03-26
US20100190801A1 (en) 2010-07-29
KR20080057299A (ko) 2008-06-24
IL190715A0 (en) 2008-11-03
DOP2006000227A (es) 2007-05-15
ZA200802369B (en) 2009-01-28
PE20070820A1 (es) 2007-09-04
TW200800987A (en) 2008-01-01
AU2006303551A1 (en) 2007-04-26
NZ567574A (en) 2010-03-26
EP1940838B1 (de) 2012-08-22
US7718669B2 (en) 2010-05-18
CN101291932A (zh) 2008-10-22
US20090030011A1 (en) 2009-01-29
UY29878A1 (es) 2007-05-31
EP1940838A1 (de) 2008-07-09
RU2008119435A (ru) 2009-11-27
HN2006035237A (es) 2010-03-11
WO2007045392A1 (de) 2007-04-26
CA2625442A1 (en) 2007-04-26
BRPI0617712A2 (pt) 2011-08-02

Similar Documents

Publication Publication Date Title
AR058095A1 (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas. procesos de obtencion y composiciones farmaceuticas.
AR056686A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas
AR038172A1 (es) Compuesto de ciclohexano y ciclohexeno, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica, procedimiento para preparar el compuesto y compuestos intermediarios en dicho procedimiento
BRPI0517568A (pt) óxido amorfo, e, transistor de efeito de campo
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
AR070469A1 (es) Derivados de naftiridina y composiciones farmaceuticas como inhibidores de quinasa con actividad sobre c- kit y pdgfr
CO6511251A2 (es) Compuestos quimicos
DOP2014000212A (es) Compuestos inhibidores de beta-lactamasas
AR043648A1 (es) Derivados de bencenosulfonamida
ECSP066826A (es) Inhibidores de integrasa de vih
AR047520A1 (es) Derivados de indazol como inhibidores de la lipasa sensible a hormonas
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
NI200800175A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias.
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
AR084430A1 (es) Di/tri-aza-espiro-alcanos c
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
AR054132A1 (es) Derivados de azolopiridin-2-ona como inhibidores de lipasas y fosfolipasas
BR112021019656A2 (pt) Formas sólidas de um inibidor de beta-lactamase dispensado por via oral e usos das mesmas
CO2021014266A2 (es) Composiciones farmacéuticas inyectables y usos de las mismas
CY1110658T1 (el) Χρηση του καρραγηνου για τη θεραπεια μολυνσεων απο ρινοϊο
PE20080342A1 (es) Inhibidores de proteasa de hiv de 2-(amino-sustituido)-benzotiazol sulfonamida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal